UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 726

Sortiert nach

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Clinical pharmacokinetics, 2010-08, Vol.49 (8), p.493-507

2010

Volltextzugriff (PDF)

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

The New England journal of medicine, 2009-07, Vol.361 (2), p.123-134

2009

Volltextzugriff (PDF)

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

Clinical pharmacokinetics, 2014-04, Vol.53 (4), p.305-325

2014

Volltextzugriff (PDF)

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

Investigational new drugs, 2015-02, Vol.33 (1), p.201-214

2015

Volltextzugriff (PDF)

Photodynamic Therapy in Oncology

The oncologist (Dayton, Ohio), 2006-10, Vol.11 (9), p.1034-1044

2006

Volltextzugriff (PDF)

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

Clinical cancer research, 2017-08, Vol.23 (16), p.4540-4544

2017

Volltextzugriff (PDF)

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Computer methods and programs in biomedicine, 2011, Vol.101 (1), p.72-79

2011

Volltextzugriff (PDF)

Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement

Clinical pharmacokinetics, 2013-06, Vol.52 (6), p.399-414

2013

Volltextzugriff (PDF)

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature medicine, 2023-05, Vol.29 (5), p.1103-1112

2023

Volltextzugriff (PDF)

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Journal of clinical oncology, 2010-05, Vol.28 (15), p.2512-2519

2010

Volltextzugriff (PDF)

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

British journal of cancer, 2021-02, Vol.124 (4), p.728-735

2021

Volltextzugriff (PDF)

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Clinical cancer research, 2011-05, Vol.17 (10), p.3455-3468

2011

Volltextzugriff (PDF)

A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

Clinical cancer research, 2004-06, Vol.10 (11), p.3717-3727

2004

Volltextzugriff (PDF)

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

European journal of cancer (1990), 2017-05, Vol.76, p.144-151

2017

Volltextzugriff (PDF)

P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel

International journal of cancer, 2013-05, Vol.132 (10), p.2439-2447

2013

Volltextzugriff (PDF)

Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review

Anti-cancer drugs, 2014-06, Vol.25 Update on Taxanes in Cancer Therapy (5), p.488-494

2014

Volltextzugriff (PDF)

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time

European journal of cancer (1990), 2016-02, Vol.54, p.40-48

2016

Volltextzugriff (PDF)

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2008-09, Vol.872 (1), p.1-22

2008

Volltextzugriff (PDF)

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

Investigational new drugs, 2012-04, Vol.30 (2), p.443-449

2012

Volltextzugriff (PDF)

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis

Antimicrobial agents and chemotherapy, 2015-01, Vol.59 (1), p.1-14

2015

Volltextzugriff (PDF)

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb–drug interactions in cancer patients

Cancer treatment reviews, 2013-11, Vol.39 (7), p.773-783

2013

Volltextzugriff (PDF)

Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities

Cancer treatment reviews, 2013-10, Vol.39 (6), p.664-672

2013

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Clinical pharmacokinetics, 2017-09, Vol.56 (9), p.987-997

2017

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Clinical cancer research, 2011-03, Vol.17 (5), p.1131-1139

2011

Volltextzugriff (PDF)

1 – 25 von 726

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(696)
Mit Volltextzugriff
(671)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(573)
Life Sciences & Biomedicine
(568)
Humans
(506)
Oncology
(304)
Female
(276)
Pharmacology & Pharmacy
(249)
Biological And Medical Sciences
(209)
Medical Sciences
(209)
Male
(206)
Middle Aged
(199)
Pharmacology. Drug Treatments
(180)
Aged
(176)
Adult
(169)
Neoplasms - Drug Therapy
(134)
Animals
(127)
Pharmacokinetics
(127)
Antineoplastic Agents
(120)
Antineoplastic Agents - Pharmacokinetics
(107)
Chemistry
(107)
Physical Sciences
(106)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

Photodynamic Therapy in Oncology

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel

Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time

Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb–drug interactions in cancer patients

Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Suchergebnisse filtern